Oklahoma Medical Research Foundation

Hough Ear Institute

Seoul National University

Rheal A Towner

Robert A Floyd

Richard Dana Kopke

Junho Chung

Jonathan Wren

The present disclosure is directed to novel monoclonal antibodies that bind to ELTD 1 and methods for use thereof, including, detection and treatment of cancer, multiple sclerosis, retinopathy, or promoting tissue regeneration.

Monoclonal antibodies to ELTD1 and uses thereof

The present disclosure describes the use of 2,4-disulfonyl phenyl tert-butyl nitron (2,4-ds-PBN) in the treatment of temozolomide drug resistant gliomas. The 2,4-ds-PBN may be used combined with other chemo- and radiotherapies and surgery, including temozolomide, to reduce glioma occurrence, recurrence, spread, growth, metastasis, and vascularization, and to inhibit development of temozolomide resistance.

Treatment of drug resistant gliomas

The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.

Adjuvant chemotherapy for anaplastic gliomas

The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl &#x3b1;-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).

Methods for treating brain injury

The present disclosure is directed to antibodies binding to ELTDI. Plexin-B2, Spondin-1, fibulin-1, LINGO I or SLIT3 and methods of using such antibodies to treat and/or diagnose gliomas. Thus, in accordance with the present disclosure, there is provided a method of inhibiting a glioma cell comprising contacting said glioma cell with a first antibody or antibody fragment that binds immunologically to ELTDI, Plexin-B2, Spondin-1 or SLIT3. The method may further comprise contacting said glioma cell with a second anti-cancer agent or treatment.

Antibodies against glioma biomarkers

Methods of treating tinnitus

The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprises 2,4-disulfonyl &#x3b1;-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).

Growing community of inventors

Piedmont, OK, United States of America

Rheal A Towner